Related Experiment Video
Updated: May 31, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
Designing modulators of dimethylarginine dimethylaminohydrolase (DDAH): a focus on selectivity over arginase
Juerke Kotthaus1, Dennis Schade, Joscha Kotthaus
1Pharmaceutical and Medicinal Chemistry, Christian-Albrechts-University, Gutenbergstr. 76-78, Kiel, Germany.
Abstract:
DDAH inhibition presents a novel promising pharmaceutical strategy to lower NO formation. To date, several potent DDAH inhibitors have been published, most of them representing analogues of l-arginine. While inhibitory effects on NOSs have already been considered, selectivity over arginase has been neglected so far. In our view, the latter selectivity is more important since an additional inhibition of arginase decreases the desired effects on NO levels. Thus, we particularly focus on selectivity over arginase. We present a comprehensive selectivity profile of known DDAH inhibitors by covering their inhibitory potency on arginase. Among the studied compounds, N(ω)-(2-methoxyethyl)-l-arginine (2a, L-257) that is already selective over NOSs also only modestly affected arginase activity and is thus far the most suitable DDAH inhibitor for pharmacological studies.
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Pharmacogenomics: Identification of New Drug Targets
Antihypertensive Drugs: Vasodilators
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Enzyme Inhibition

